PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4)

• Catherine M Broome,
• Donald Arnold,
• Caroline Piatek,
• Eun-Ju Lee,
• Hany Zayed,
• Stanford Peng,
• Ismail Simsek

Affiliations

Catherine M Broome

1 MedStar Georgetown University Hospital, Washington, United States

Donald Arnold

2 McMaster University, Department of Medicine, Hamilton, Canada

Caroline Piatek

3 University of Southern California, Jane Anne Nohl Division of Hematology, Los Angeles, United States

Eun-Ju Lee

4 New York Presbyterian Hospital - Weill Cornell Medicine, Division of Hematology and Medical Oncology, New York, United States

Hany Zayed

5 Alpine Immune Sciences, Inc., Seattle, United States

Stanford Peng

5 Alpine Immune Sciences, Inc., Seattle, United States

Ismail Simsek

5 Alpine Immune Sciences, Inc., Seattle, United States